BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36097320)

  • 1. Population Pharmacokinetic Modeling Combined With Machine Learning Approach Improved Tacrolimus Trough Concentration Prediction in Chinese Adult Liver Transplant Recipients.
    Li ZR; Li RD; Niu WJ; Zheng XY; Wang ZX; Zhong MK; Qiu XY
    J Clin Pharmacol; 2023 Mar; 63(3):314-325. PubMed ID: 36097320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Donor and Recipient
    Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J
    Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346
    [No Abstract]   [Full Text] [Related]  

  • 3. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
    Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
    J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving prediction of tacrolimus concentration using a combination of population pharmacokinetic modeling and machine learning in chinese renal transplant recipients.
    Wang YP; Lu XL; Shao K; Shi HQ; Zhou PJ; Chen B
    Front Pharmacol; 2024; 15():1389271. PubMed ID: 38783953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
    Fukudo M; Yano I; Masuda S; Goto M; Uesugi M; Katsura T; Ogura Y; Oike F; Takada Y; Egawa H; Uemoto S; Inui K
    Clin Pharmacol Ther; 2006 Oct; 80(4):331-45. PubMed ID: 17015051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?
    Brooks E; Tett SE; Isbel NM; Staatz CE
    Clin Pharmacokinet; 2016 Nov; 55(11):1295-1335. PubMed ID: 27138787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.
    Chen B; Shi HQ; Liu XX; Zhang WX; Lu JQ; Xu BM; Chen H
    J Clin Pharm Ther; 2017 Dec; 42(6):679-688. PubMed ID: 28833329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual dose recommendations for drug interaction between tacrolimus and voriconazole in adult liver transplant recipients: A semiphysiologically based population pharmacokinetic modeling approach.
    Li ZR; Shen CH; Li RD; Wang B; Li J; Niu WJ; Zhang LJ; Zhong MK; Wang ZX; Qiu XY
    Eur J Pharm Sci; 2023 May; 184():106405. PubMed ID: 36775255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients.
    Zhu W; Xue L; Peng H; Duan Z; Zheng X; Cao D; Wen J; Wei X
    Pharmacogenomics; 2018 Aug; 19(13):1013-1025. PubMed ID: 30040022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.
    Moes DJ; van der Bent SA; Swen JJ; van der Straaten T; Inderson A; Olofsen E; Verspaget HW; Guchelaar HJ; den Hartigh J; van Hoek B
    Eur J Clin Pharmacol; 2016 Feb; 72(2):163-74. PubMed ID: 26521259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
    Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
    Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.
    Zhao CY; Jiao Z; Mao JJ; Qiu XY
    Br J Clin Pharmacol; 2016 May; 81(5):891-907. PubMed ID: 26574188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.
    Li D; Lu W; Zhu JY; Gao J; Lou YQ; Zhang GL
    J Clin Pharm Ther; 2007 Oct; 32(5):505-15. PubMed ID: 17875118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach.
    Lu Y; Xu L; Cui J; Shen S; Li X
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1385-1394. PubMed ID: 34133842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.
    Andreu F; Colom H; Elens L; van Gelder T; van Schaik RHN; Hesselink DA; Bestard O; Torras J; Cruzado JM; GrinyĆ³ JM; Lloberas N
    Clin Pharmacokinet; 2017 Aug; 56(8):963-975. PubMed ID: 28050888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial Neural Network Analysis of Determinants of Tacrolimus Pharmacokinetics in Liver Transplant Recipients.
    Du Y; Zhang Y; Yang Z; Li Y; Wang X; Li Z; Ren L; Li Y
    Ann Pharmacother; 2024 May; 58(5):469-479. PubMed ID: 37559252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.